Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Approves ANDA081095 for Oral Acetaminophen/Aspirin/Codeine Capsule (Discontinued)
The FDA granted approval for labeling and manufacturing submissions for ANDA081095, a discontinued oral capsule combining acetaminophen, aspirin, and codeine phosphate, sponsored by MIKART.
Actualizaciones regulatorias
9 sept 2026•1 min de lectura
FDA Approves ANDA089479 for Acetaminophen/Codeine Phosphate Tablet (Discontinued)
The FDA granted approval for ANDA089479, submitted by AM THERAP, for an oral tablet containing 300 mg acetaminophen and 30 mg codeine phosphate. The product is listed as discontinued.
Actualizaciones regulatorias
8 sept 2026•1 min de lectura
FDA Discontinues PROVAL #3 Oral Capsule (ANDA085685)
FDA records show PROVAL #3 oral capsule, containing 325 mg acetaminophen and 30 mg codeine phosphate, is now discontinued. Sponsor: Solvay. ANDA085685.
Actualizaciones regulatorias
5 sept 2026•1 min de lectura
FDA Approves ANDA085964 for Acetaminophen and Codeine Phosphate Tablet
The FDA approved ANDA085964 for Sandoz's oral tablet containing 300 mg acetaminophen and 60 mg codeine phosphate; the product is listed as discontinued after multiple labeling submissions.
Actualizaciones regulatorias
30 ago 2026•1 min de lectura
FDA Approves KV PHARM Acetaminophen/Codeine Phosphate Tablet (ANDA085288)
FDA approved KV PHARM's oral tablet containing 300 mg acetaminophen and 30 mg codeine phosphate (ANDA085288). Multiple labeling submissions were filed; the product is now discontinued.